Skip to main content

Advertisement

SpringerLink
Log in

Long-term survival in advanced non-squamous NSCLC patients treated with first-line bevacizumab-based therapy

  • Research Article
  • Published:
Clinical and Translational Oncology Aims and scope Submit manuscript

Abstract

Background/Aim

First-line bevacizumab-based therapies have been shown to improve clinical outcomes in patients with non-squamous non-small-cell lung cancer (NSCLC). We aimed to descriptively analyse patients with non-squamous NSCLC who received a long-term period of maintenance bevacizumab.

Patients and methods

This retrospective study included 104 patients who had already reached a progression-free survival (PFS) of at least 9 months.

Results

Median overall survival and PFS were 30.7 and 15.1 months, respectively. The overall response rate was 83 %. Weight loss ≤5 %, ECOG PS = 0, or low number of metastatic sites seem to be predictive factors of good evolution. The incidence of bevacizumab-related adverse events appeared to be similar as the previous studies.

Conclusion

Our findings show that there is a long-term survivor group whom the administration of bevacizumab resulted in a relevant prolongation of response without new safety signals. Due to the population heterogeneity, it was not possible to identify the standardised predictive factors.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3

Similar content being viewed by others

References

  1. Ferlay J, Soerjomataram I, Dikshit R, Eser S, Mathers C, Rebelo M, et al. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer. 2015;136(5):E359–86.

    Article  CAS  PubMed  Google Scholar 

  2. Malvezzi M, Bertuccio P, Levi F, La VC, Negri E. European cancer mortality predictions for the year 2012. Ann Oncol. 2012;23(4):1044–52.

    Article  CAS  PubMed  Google Scholar 

  3. Goldstraw P, Crowley J, Chansky K, Giroux DJ, Groome PA, Rami-Porta R, et al. The IASLC lung cancer staging project: proposals for the revision of the TNM stage groupings in the forthcoming (seventh) edition of the TNM Classification of malignant tumours. J Thorac Oncol. 2007;2(8):706–14.

    Article  PubMed  Google Scholar 

  4. Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell. 2011;144(5):646–74.

    Article  CAS  PubMed  Google Scholar 

  5. Zhan P, Wang J, Lv XJ, Wang Q, Qiu LX, Lin XQ, et al. Prognostic value of vascular endothelial growth factor expression in patients with lung cancer: a systematic review with meta-analysis. J Thorac Oncol. 2009;4(9):1094–103.

    Article  PubMed  Google Scholar 

  6. Ferrara N, Hillan KJ, Gerber HP, Novotny W. Discovery and development of bevacizumab, an anti-VEGF antibody for treating cancer. Nat Rev Drug Discov. 2004;3(5):391–400.

    Article  CAS  PubMed  Google Scholar 

  7. Johnson DH, Fehrenbacher L, Novotny WF, Herbst RS, Nemunaitis JJ, Jablons DM, et al. Randomized phase II trial comparing bevacizumab plus carboplatin and paclitaxel with carboplatin and paclitaxel alone in previously untreated locally advanced or metastatic non-small-cell lung cancer. J Clin Oncol. 2004;22(11):2184–91.

    Article  CAS  PubMed  Google Scholar 

  8. Niho S, Kunitoh H, Nokihara H, Horai T, Ichinose Y, Hida T, et al. Randomized phase II study of first-line carboplatin-paclitaxel with or without bevacizumab in Japanese patients with advanced non-squamous non-small-cell lung cancer. Lung Cancer. 2012;76(3):362–7.

    Article  PubMed  Google Scholar 

  9. Reck M, von PJ, Zatloukal P, Ramlau R, Gorbounova V, Hirsh V, et al. Phase III trial of cisplatin plus gemcitabine with either placebo or bevacizumab as first-line therapy for nonsquamous non-small-cell lung cancer: AVAil. J Clin Oncol. 2009;27(8):1227–34.

    Article  CAS  PubMed  Google Scholar 

  10. Reck M, von PJ, Zatloukal P, Ramlau R, Gorbounova V, Hirsh V, et al. Overall survival with cisplatin-gemcitabine and bevacizumab or placebo as first-line therapy for nonsquamous non-small-cell lung cancer: results from a randomised phase III trial (AVAiL). Ann Oncol. 2010;21(9):1804–9.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  11. Sandler A, Gray R, Perry MC, Brahmer J, Schiller JH, Dowlati A, et al. Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. N Engl J Med. 2006;355(24):2542–50.

    Article  CAS  PubMed  Google Scholar 

  12. Zhou C, Wu YL, Chen G, Liu X, Zhu Y, Lu S, et al. BEYOND: a randomized, double-blind, placebo-controlled, multicenter, phase III study of first-line carboplatin/paclitaxel plus bevacizumab or placebo in Chinese patients with advanced or recurrent nonsquamous non-small-cell lung cancer. J Clin Oncol. 2015;33(19):2197–204.

    Article  CAS  PubMed  Google Scholar 

  13. Crino L, Dansin E, Garrido P, Griesinger F, Laskin J, Pavlakis N, et al. Safety and efficacy of first-line bevacizumab-based therapy in advanced non-squamous non-small-cell lung cancer (SAiL, MO19390): a phase 4 study. Lancet Oncol. 2010;11(8):733–40.

    Article  CAS  PubMed  Google Scholar 

  14. Lopez-Chavez A, Young T, Fages S, Leon L, Schiller JH, Dowlati A, et al. Bevacizumab maintenance in patients with advanced non-small-cell lung cancer, clinical patterns, and outcomes in the eastern cooperative oncology group 4599 study: results of an exploratory analysis. J Thorac Oncol. 2012;7(11):1707–12.

    Article  CAS  PubMed  Google Scholar 

  15. Nadler E, Yu E, Ravelo A, Sing A, Forsyth M, Gruschkus S. Bevacizumab treatment to progression after chemotherapy: outcomes from a U.S. community practice network. Oncologist. 2011;16(4):486–96.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  16. Soria JC, Mauguen A, Reck M, Sandler AB, Saijo N, Johnson DH, et al. Systematic review and meta-analysis of randomised, phase II/III trials adding bevacizumab to platinum-based chemotherapy as first-line treatment in patients with advanced non-small-cell lung cancer. Ann Oncol. 2013;24(1):20–30.

    Article  PubMed  Google Scholar 

  17. Berman RS, Portera CA Jr, Ellis LM. Biology of liver metastases. Cancer Treat Res. 2001;109:183–206.

    Article  CAS  PubMed  Google Scholar 

  18. Nathoo N, Chahlavi A, Barnett GH, Toms SA. Pathobiology of brain metastases. J Clin Pathol. 2005;58(3):237–42.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  19. Preusser M, Capper D, Ilhan-Mutlu A, Berghoff AS, Birner P, Bartsch R, et al. Brain metastases: pathobiology and emerging targeted therapies. Acta Neuropathol. 2012;123(2):205–22.

    Article  CAS  PubMed  Google Scholar 

  20. Bar J, Goss GD. Tumor vasculature as a therapeutic target in non-small cell lung cancer. J Thorac Oncol. 2012;7(3):609–20.

    Article  CAS  PubMed  Google Scholar 

  21. Folkman J, Ryeom S. Is oncogene addiction angiogenesis-dependent? Cold Spring Harb Symp Quant Biol. 2005;70:389–97.

    Article  CAS  PubMed  Google Scholar 

  22. Barlesi F, Scherpereel A, Rittmeyer A, Pazzola A, Ferrer TN, Kim JH, et al. Randomized phase III trial of maintenance bevacizumab with or without pemetrexed after first-line induction with bevacizumab, cisplatin, and pemetrexed in advanced nonsquamous non-small-cell lung cancer: AVAPERL (MO22089). J Clin Oncol. 2013;31(24):3004–11.

    Article  CAS  PubMed  Google Scholar 

  23. Johnson BE, Kabbinavar F, Fehrenbacher L, Hainsworth J, Kasubhai S, Kressel B, et al. ATLAS: randomized, double-blind, placebo-controlled, phase IIIB trial comparing bevacizumab therapy with or without erlotinib, after completion of chemotherapy, with bevacizumab for first-line treatment of advanced non-small-cell lung cancer. J Clin Oncol. 2013;31(31):3926–34.

    Article  CAS  PubMed  Google Scholar 

  24. Patel JD, Socinski MA, Garon EB, Reynolds CH, Spigel DR, Olsen MR, et al. PointBreak: a randomized phase III study of pemetrexed plus carboplatin and bevacizumab followed by maintenance pemetrexed and bevacizumab versus paclitaxel plus carboplatin and bevacizumab followed by maintenance bevacizumab in patients with stage IIIB or IV nonsquamous non-small-cell lung cancer. J Clin Oncol. 2013;31(34):4349–57.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  25. Dansin E, Cinieri S, Garrido P, Griesinger F, Isla D, Koehler M, et al. MO19390 (SAiL): bleeding events in a phase IV study of first-line bevacizumab with chemotherapy in patients with advanced non-squamous NSCLC. Lung Cancer. 2012;76(3):373–9.

    Article  PubMed  Google Scholar 

  26. Kosty MP, Brahmer JR, Jahanzeb M, Kumar P, Robles R, Wozniak AJ, et al. Use of bevacizumab (BV) after induction therapy is associated with survival benefit in patients (pts) with non-small cell lung cancer (NSCLC) in the ARIES observational cohort study (OCS). Eur J Cancer. 2011;47(Suppl. 1):598 (abstr. 9020).

    Article  Google Scholar 

  27. Mok T, Gorbunova V, Juhasz E, Szima B, Burdaeva O, Orlov S, et al. A correlative biomarker analysis of the combination of bevacizumab and carboplatin-based chemotherapy for advanced nonsquamous non-small-cell lung cancer: results of the phase II randomized ABIGAIL study (BO21015). J Thorac Oncol. 2014;9(6):848–55.

    Article  CAS  PubMed  Google Scholar 

  28. Massuti B, Jantus-Lewintre E, Gonzalez Arriba JL, Rodriguez Abreu D, Juan O, Domine M et al (2014) ANGIOMET: analysis of the correlations between angiogenic markers and outcome in patients (p) with advanced nonsquamous NSCLC (NS-NSCLC) treated with carboplatin, paclitaxel, and bevacizumab (CPB). J Clin Oncol 32, 2014 (suppl; abstr e19014).

Download references

Acknowledgments

Medical writing support was provided by Ana López-Ballesteros and Antonio Torres at Dynamic S.L., during the preparation of this paper. This work was supported by Roche Farma, S.A., Spain.

Author information

Authors and Affiliations

  1. Medical Oncology Unit––Department of Translational Oncology, Hospital Universitario La Paz-IDIPAZ, Paseo de la Castellana, 261, 28046, Madrid, Spain

    J. De Castro

  2. Hospital Clínico Universitario San Carlos, Madrid, Spain

    J. L. González-Larriba

  3. Hospital Universitario Lucus Augusti, Lugo, Spain

    S. Vázquez

  4. Hospital General Universitario de Alicante, Alicante, Spain

    B. Massutí

  5. MD Anderson Cancer Center Madrid, Madrid, Spain

    J. M. Sanchez-Torres

  6. Fundación Jiménez Díaz, Madrid, Spain

    M. Dómine

  7. Hospital Ramón y Cajal, Madrid, Spain

    P. Garrido

  8. Centro Integral Oncológico Clara Campal, Madrid, Spain

    A. Calles

  9. Hospital Universitario Miguel Servet, Saragossa, Spain

    A. Artal

  10. Hospital San Pedro de Alcántara, Cáceres, Spain

    R. Collado

  11. Hospital Universitario Gregorio Marañón, Madrid, Spain

    R. García

  12. Hospital Infanta Sofía, Madrid, Spain

    M. Sereno

  13. Hospital de la Santa Creu i Sant Pau, Barcelona, Spain

    M. Majem

  14. Hospital General Universitario Morales Meseguer, Murcia, Spain

    J. A. Macías

  15. Hospital Arnau Vilanova, Valencia, Spain

    O. Juan

  16. Hospital La Fe, Valencia, Spain

    J. Gómez-Codina

  17. Complejo Hospitalario de Navarra––Hospital de Navarra, Pamplona, Spain

    B. Hernández

  18. Complexo Hospitalario Universitario de Vigo, Pontevedra, Spain

    M. Lázaro

  19. Complejo Hospitalario de Jaén, Jaén, Spain

    A. L. Ortega

  20. Hospital Regional Universitario Carlos Haya, Málaga, Spain

    M. Cobo

  21. Hospital Universitario Virgen de la Victoria, Málaga, Spain

    J. M. Trigo

  22. Institut Català d’Oncologia-Hospital Universitari Germans Trias i Pujol, Barcelona, Spain

    E. Carcereny

  23. University Hospital of Antwerp, Antwerp, Belgium

    C. Rolfo

  24. Hospital General Universitario de Elda, Alicante, Spain

    S. Macia

  25. Hospital Universitario Doctor Peset, Valencia, Spain

    J. Muñoz

  26. Complejo Asistencial Universitario de León, León, Spain

    P. Diz

  27. Hospital Universitario de Móstoles, Madrid, Spain

    M. Méndez

  28. Complejo Hospitalario Torrecárdenas, Almería, Spain

    F. Rosillo

  29. Hospital Universitario Virgen del Rocío, Seville, Spain

    L. Paz-Ares

  30. Roche Farma, S.A., Madrid, Spain

    J. V. Cardona

  31. Hospital Clínico Universitario Lozano Blesa, Saragossa, Spain

    D. Isla

Authors
  1. J. De Castro
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. J. L. González-Larriba
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. S. Vázquez
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. B. Massutí
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. J. M. Sanchez-Torres
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. M. Dómine
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. P. Garrido
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. A. Calles
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. A. Artal
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. R. Collado
    View author publications

    You can also search for this author in PubMed Google Scholar

  11. R. García
    View author publications

    You can also search for this author in PubMed Google Scholar

  12. M. Sereno
    View author publications

    You can also search for this author in PubMed Google Scholar

  13. M. Majem
    View author publications

    You can also search for this author in PubMed Google Scholar

  14. J. A. Macías
    View author publications

    You can also search for this author in PubMed Google Scholar

  15. O. Juan
    View author publications

    You can also search for this author in PubMed Google Scholar

  16. J. Gómez-Codina
    View author publications

    You can also search for this author in PubMed Google Scholar

  17. B. Hernández
    View author publications

    You can also search for this author in PubMed Google Scholar

  18. M. Lázaro
    View author publications

    You can also search for this author in PubMed Google Scholar

  19. A. L. Ortega
    View author publications

    You can also search for this author in PubMed Google Scholar

  20. M. Cobo
    View author publications

    You can also search for this author in PubMed Google Scholar

  21. J. M. Trigo
    View author publications

    You can also search for this author in PubMed Google Scholar

  22. E. Carcereny
    View author publications

    You can also search for this author in PubMed Google Scholar

  23. C. Rolfo
    View author publications

    You can also search for this author in PubMed Google Scholar

  24. S. Macia
    View author publications

    You can also search for this author in PubMed Google Scholar

  25. J. Muñoz
    View author publications

    You can also search for this author in PubMed Google Scholar

  26. P. Diz
    View author publications

    You can also search for this author in PubMed Google Scholar

  27. M. Méndez
    View author publications

    You can also search for this author in PubMed Google Scholar

  28. F. Rosillo
    View author publications

    You can also search for this author in PubMed Google Scholar

  29. L. Paz-Ares
    View author publications

    You can also search for this author in PubMed Google Scholar

  30. J. V. Cardona
    View author publications

    You can also search for this author in PubMed Google Scholar

  31. D. Isla
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to J. De Castro.

Ethics declarations

Ethical standards

This study was conducted in accordance with the Declaration of Helsinki, all its amendments, and national regulations. The study was approved by the Clinical Research Ethic Committee at Hospital Universitario La Paz (Madrid, Spain) and all patients gave their informed consent before study inclusion.

Conflict of interest

Dr. de Castro provided Scientific advice to Roche Farma S.A; Dr. Massuti participated as an Advisor for Roche Farma S.A.; Dr. Rolfo received a research grant from Sanofi Aventis, he was also a Speaker Bureau for Novartis, and received consultancy fees from Mylan Pharmaceuticals and Oncopass; Dr. Paz-Ares provided Scientific advice to Roche Farma S.A.; and JV Cardona was an employee for Roche Farma S.A. None of the other authors has declared any conflict of interest.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

De Castro, J., González-Larriba, J.L., Vázquez, S. et al. Long-term survival in advanced non-squamous NSCLC patients treated with first-line bevacizumab-based therapy. Clin Transl Oncol 19, 219–226 (2017). https://doi.org/10.1007/s12094-016-1527-8

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s12094-016-1527-8

Keywords

Search

Navigation